Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News


Will digital therapeutics complement or replace stimulant medications to address inattention and “silent” cognitive issues?


Akili Inter­ac­tive: Dig­i­tal pedi­atric ADHD ther­a­peu­tic per­forms well with or with­out accom­pa­ny­ing stim­u­lant ther­a­py (Mobi­Health News):

Dig­i­tal ther­a­peu­tic com­pa­ny Akili Inter­ac­tive has announced the first results of an open-label, mul­ti­site pedi­atric ADHD tri­al pro­vid­ing some patients with the company’s video game-like treat­ment along­side a stim­u­lant med­ica­tion.

Accord­ing to the com­pa­ny, both those who received the AKL-T01 ther­a­py with (n = 130) or with­out (n = 76) accom­pa­ny­ing stim­u­lant med­ica­tion saw sig­nif­i­cant improve­ments one month after base­line (p < .001) as mea­sured by the trial’s pri­ma­ry out­come, rat­ings on the ADHD Impair­ment Rat­ing Scale (IRS) report­ed by par­ents … While a full report­ing of the study data is still being pre­pared for upcom­ing con­fer­ences or jour­nal pub­li­ca­tion, Akili views these find­ings as evi­dence that AKL-T01 pro­vides a ben­e­fit “inde­pen­dent of whether the chil­dren were on or off ADHD med­ica­tion.”

The Study:

Akili Study of AKL-T01 With and With­out Stim­u­lant Med­ica­tion in Chil­dren With ADHD Achieves Pri­ma­ry Effi­ca­cy End­point (press release):

Fol­low­ing our suc­cess­ful piv­otal STARS-ADHD study of AKL-T01 as a poten­tial treat­ment for inat­ten­tion in chil­dren with ADHD not tak­ing stim­u­lant med­ica­tions, under­stand­ing the ben­e­fit of our tech­nol­o­gy when used along­side ADHD med­ica­tions has been a research pri­or­i­ty for us. Impor­tant­ly, par­ents see improve­ments in their chil­dren regard­less of whether they are using the treat­ment alone or along­side stim­u­lants,” said Eddie Mar­tuc­ci, CEO of Akili. “As we con­tin­ue to work toward FDA clear­ance for this nov­el ther­a­peu­tic for inat­ten­tion in chil­dren with ADHD, these data and the ben­e­fits expressed by par­ents and physi­cians in this study lend fur­ther cre­dence to the impor­tant role AKL-T01 can play in the treat­ment of ADHD.”

More than 5.5 mil­lion chil­dren diag­nosed with ADHD strug­gle with atten­tion issues. Inat­ten­tion and oth­er “silent” cog­ni­tive issues often go unrec­og­nized in the face of oth­er more overt dis­ease symp­toms, yet they sig­nif­i­cant­ly impact dai­ly func­tion­ing. “Chil­dren with ADHD are joined by mil­lions of oth­ers, both with and with­out med­ical diag­noses, who expe­ri­ence chal­lenges in their dai­ly lives due to inat­ten­tion or oth­er cog­ni­tive issues. We’re com­mit­ted to dri­ving greater aware­ness and recog­ni­tion of the impact of these cog­ni­tive issues and advanc­ing nov­el approach­es to help all those affect­ed,” said Anil Jina, M.D., Akili’s Chief Med­ical Offi­cer.

News in Context:


Leave a Reply...

Loading Facebook Comments ...

Leave a Reply

Categories: Attention and ADD/ADHD, Cognitive Neuroscience, Health & Wellness, Technology

Tags: , , , , , , , , , , , ,

Search in our Archives

Watch All Recordings Now (40+ Speakers, 12+ Hours)

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters,  SharpBrains is an independent market research firm tracking how brain science can improve our health and our lives.

Follow us and Engage via…

RSS Feed